Renin Angiotensin Aldosterone System (RAAS): Its biology and drug targets for treating diabetic nephropathy

Pakistan Journal of Pharmaceutical Sciences

Volumn 27, Issue 5, 2014, Pages 1379-1391

  Zain, Maryam ^a,b   Awan, Fazli Rabbi ^a,b  

^a NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

^b PAKISTAN INSTITUTE OF ENGINEERING AND APPLIED SCIENCES   (Pakistan)

Author keywords

ACE; Aldosterone; Angiotensin; Diabetic nephropathy; Renin

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN; RENIN INHIBITOR;

BLOOD PRESSURE REGULATION; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE COURSE; DNA POLYMORPHISM; DRUG TARGETING; END STAGE RENAL DISEASE; GENE MUTATION; GLYCEMIC CONTROL; HEREDITY; HUMAN; INSULIN RESPONSE; MICROALBUMINURIA; PATHOGENESIS; PATHOPHYSIOLOGY; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; PHYSIOLOGY; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84907819312     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (113)

1. Abe M, Maruyama N, Yoshida Y, Ito M, Okada K and Soma M (2011). Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. Endocr. J., 58: 663-674.
2. ADA (2008). Diagnosis and classification of diabetes mellitus. Diabetes Care, 31: S55-60.
3. Bain SC and Chowdhury TA (2000). Genetics of diabetic nephropathy and microalbuminuria. J. R. Soc. Med., 93: 62-66.
4. Baird TE, Palmer BR, Frampton CM, Yandle TG, Skelton L, Richards AM and Cameron VA (2007). Association of the aldosterone synthase gene C-344T polymorphism with risk factors and survival in a post-myocardial infarction cohort. J. Hum. Hypertens., 21: 256-258.
5. Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D and Davis P (2008). Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int., 73: 1303-1309.
6. Barnett A (2006). Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J. Am. Soc. Nephrol., 17: S132-135.
7. Barrios V, Coca A, Escobar C, Enrique R and Rincon LM (2012). Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice. Expert Rev. Cardiovasc. Ther., 10: 159-166.
8. Borecki IB, Province MA, Ludwig EH, Ellison RC, Folsom AR, Heiss G, Lalouel JM, Higgins M and Rao DC (1997). Associations of candidate loci angiotensinogen and angiotensin-converting enzyme with severe hypertension: The NHLBI Family Heart Study. Ann. Epidemiol., 7: 13-21.
9. Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, Corvol P, Pascoe L and Soubrier F (1998). Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension, 32: 198-204.
10. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P and Clark AJ (1994). Linkage of the angiotensinogen gene to essential hypertension. N. Engl. J. Med., 330: 1629-1633.
11. Corvol P and Jeunemaitre X (1997). Molecular genetics of human hypertension: role of angiotensinogen. Endocr. Rev., 18: 662-677.
12. Davies E and Kenyon CJ (2003). CYP11B2 polymorphisms and cardiovascular risk factors. J. Hypertens., 21: 1249-1253.
13. Doria A, Onuma T, Gearin G, Freire MB, Warram JH and Krolewski AS (1996). Angiotensinogen polymorphism M235T, hypertension, and nephropathy in insulin-dependent diabetes. Hypertension, 27: 1134-1139.
14. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM and de Zeeuw D (2007). Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol., 18: 1540-1546.
15. Ekinci EI, Thomas G, Thomas D, Johnson C, Macisaac RJ, Houlihan CA, Finch S, Panagiotopoulos S, O'Callaghan C and Jerums G (2009). Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care, 32: 1398-1403.
16. Erdos EG (1990). Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension, 16: 363-370.
17. Eyileten T, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, Vural A, Yenicesu M and Yilmaz MI (2010). Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology (Carlton), 15: 225-229.
18. Fernandez Juarez G, Luno J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernandez Vega F, Tato A and Gutierrez E (2013). Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am. J. Kidney Dis., 61: 211-218.
19. Fogari R, Mugellini A, Zoppi A, Preti P, Maffioli P, Perrone T and Derosa G (2013). Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. Expert Opin. Pharmacother., 14: 371-384.
20. Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR and Peduzzi P (2009). Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin. J. Am. Soc. Nephrol., 4: 361-368.
21. Galindo-Ocana J, Bernabeu-Wittel M, Formiga F, Fuertes-Martin A, Baron-Franco B, Murcia-Zaragoza JM, Moreno-Gavino L and Ollero-Baturone M (2012). Effects of renin-angiotensin blockers/inhibitors and statins on mortality and functional impairment in polypathological patients. Eur. J. Intern. Med., 23: 179-184.
22. Galle J, Schwedhelm E, Pinnetti S, Boger RH and Wanner C (2008). Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol. Dial. Transplant., 23: 3174-3183.
23. Gallego PH, Shephard N, Bulsara MK, van Bockxmeer FM, Powell BL, Beilby JP, Arscott G, Le Page M, Palmer LJ, Davis EA, Jones TW and Choong CS (2008). Angiotensinogen gene T235 variant: a marker for the development of persistent microalbuminuria in children and adolescents with type 1 diabetes mellitus. J. Diabetes Complications, 22: 191-198.
24. Gomez-Angelats E, de la Sierra A, Enjuto M, Sierra C, Oriola J, Francino A, Pare JC, Poch E and Coca A (2000). Lack of association between ACE gene polymorphism and left ventricular hypertrophy in essential hypertension. J. Hum. Hypertens., 14: 47-49.
25. Granier C, Makni K, Molina L, Jardin-Watelet B, Ayadi H and Jarraya F (2008). Gene and protein markers of diabetic nephropathy. Nephrol. Dial. Transplant., 23: 792-799.
26. Guney I, Selcuk NY, Altintepe L, Atalay H, Basarali MK and Buyukbas S (2009). Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease. Ren. Fail., 31: 779-784.
27. Han SW, Won YW, Yi JH and Kim HJ (2007). No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol. Dial. Transplant., 22: 1150-1155.
28. Hershon KS (2011). Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease. Endocr. Pract., 17: 430-440.
29. Hobart PM, Fogliano M, O'Connor BA, Schaefer IM and Chirgwin JM (1984). Human renin gene: structure and sequence analysis. Proc. Natl. Acad. Sci. U. S. A., 81: 5026-5030.
30. Holdiness A, Monahan K, Minor D and de Shazo RD (2011). Renin Angiotensin Aldosterone System Blockade: Little to No Rationale for ACE Inhibitor and ARB Combinations. Am. J. Med., 124: 15-19.
31. Hollenberg NK, Fisher ND, Nussberger J, Moukarbel GV, Barkoudah E and Danser AH (2011). Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients? J. Hypertens., 29: 2454-2461.
32. Horky K (2010). [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases]. Vnitr. Lek., 56: 120-126.
33. Jacobsen P, Andersen S, Jensen BR and Parving HH (2003). Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J. Am. Soc. Nephrol., 14: 992-999.
34. Jacobsen P, Rossing K and Parving HH (2004). Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Curr. Opin. Nephrol. Hypertens., 13: 319-324.
35. Jarmuzewska EA, Rocchi R, Guidoni A and Mangoni AA (2008). ACE inhibitor-based treatment and antihypertensive effects in patients with type 2 diabetes. Panminerva Med., 50: 207-216.
36. Jeunemaitre X, Inoue I, Williams C, Charru A, Tichet J, Powers M, Sharma AM, Gimenez-Roqueplo AP, Hata A, Corvol P and Lalouel JM (1997). Haplotypes of angiotensinogen in essential hypertension. Am. J. Hum. Genet., 60: 1448-1460.
37. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM and et al. (1992). Molecular basis of human hypertension: role of angiotensinogen. Cell, 71: 169-180.
38. Ketelhut R and Bramlage P (2010). Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study. Clin. Drug Investig., 30: 301-311.
39. Khosla N, Kalaitzidis R and Bakris GL (2009). Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am. J. Nephrol., 30: 418-424.
40. Kiema TR, Kauma H, Rantala AO, Lilja M, Reunanen A, Kesaniemi YA and Savolainen MJ (1996). Variation at the angiotensin-converting enzyme gene and angiotensinogen gene loci in relation to blood pressure. Hypertension, 28: 1070-1075.
41. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N and Smithies O (1995). Genetic control of blood pressure and the angiotensinogen locus. Proc. Natl. Acad. Sci. U. S. A., 92: 2735-2739.
42. Kintscher U, Bramlage P, Paar WD, Thoenes M and Unger T (2007). Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol., 6: 12.
43. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P and Andress DL (2011). Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J. Am. Soc. Nephrol., 22: 763-772.
44. Krairittichai U and Chaisuvannarat V (2009). Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. J. Med. Assoc. Thai., 92: 611-617.
45. Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S and Zhang Z (2006). Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin. Exp. Nephrol., 10: 193-200.
46. Lambers Heerspink HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E, de Graeff PA and de Zeeuw D (2012). Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int., 82: 330-337.
47. Lazich I and Bakris GL (2011). Newer renin-angiotensin-aldosterone system blocker combinations: is there an advantage? Curr. Opin. Nephrol. Hypertens., 20: 471-475.
48. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J and Eknoyan G (2003). National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med., 139: 137-147.
49. Lieberman J and Sastre A (1980). Serum angiotensin-converting enzyme: elevations in diabetes mellitus. Ann. Intern. Med., 93: 825-826.
50. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman JM and Snapinn S (2002). Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens., 20: 1879-1886.
51. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C and Zoccali C (2003). The importance of diabetic nephropathy in current nephrological practice. Nephrol. Dial. Transplant., 18: 1716-1725.
52. Lteif AA, Chisholm RL, Gilbert K, Considine RV and Mather KJ (2012). Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension. Diabetes. Obes. Metab., 14: 254-261.
53. Luther JM and Brown NJ (2011). The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol. Sci., 32: 734-739.
54. Maharjan BR, Bhandary S, Risal P, Sedhain A, Shakya PR and Gautam M (2010). Microalbuminuria and macroalbuminuria in type 2 diabetes. J. Nepal. Health Res. Counc., 8: 110-115.
55. Mann JF, Anderson C, Gao P, Gerstein HC, Boehm M, Ryden L, Sleight P, Teo KK and Yusuf S (2013). Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J. Hypertens., 31: 414-421.
56. Marre M (1996). Diabetic nephropathy: the ACE hypothesis. J. Diabetes Complications, 10: 126-128.
57. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, Cambien F, Passa P and Alhenc-Gelas F (1994). Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes, 43: 384-388.
58. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P and Alhenc-Gelas F (1997). Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J. Clin. Invest., 99: 1585-1595.
59. Matsushita K, Muramatsu T, Kondo T, Maeda K, Shintani S and Murohara T (2010). Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance. J. Cardiol., 56: 111-117.
60. Min P, Jiang MH, Wei MF, Liu ZH, Jiang WP, Geng HH, Cui ZC, Zhang DL and Zhu JH (2009). Association of angiotensin-converting enzyme gene 2350G>A polymorphism with myocardial infarction in a Chinese population. Clin. Appl. Thromb. Hemost., 15: 435-442.
61. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW and Cooper ME (2000). Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ, 321: 1440-1444.
62. Montanari A, Pela G, Musiari L, Crocamo A, Boeti L, Cabassi A, Biggi A and Cherney DZ (2013). Nitric oxide-angiotensin II interactions and renal hemodynamic function in patients with uncomplicated type 1 diabetes. Am. J. Physiol. Renal Physiol., 305: F42-51.
63. Ng DP, Tai BC, Koh D, Tan KW and Chia KS (2005). Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia., 48: 1008-1016.
64. Ogawa S, Mori T, Nako K and Ito S (2008). Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens. Res., 31: 1147-1155.
65. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J and Pfeffer MA (2009). Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant., 24: 1663-1671.
66. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P and Pfeffer MA (2012). Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med., 367: 2204-2213.
67. Parving HH, Persson F, Lewis JB, Lewis EJ and Hollenberg NK (2008). Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med., 358: 2433-2446.
68. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK and Parving HH (2012). Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study. J. Renin Angiotensin Aldosterone Syst., 13: 250-253.
69. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E and Parving HH (2010). Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia, 53: 1576-1580.
70. Prasad P, Tiwari AK, Kumar KM, Ammini AC, Gupta A, Gupta R, Sharma AK, Rao AR, Nagendra R, Chandra TS, Tiwari SC, Rastogi P, Gupta BL and Thelma BK (2006). Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med. Genet., 7: 42.
71. Pratt RE, Flynn JA, Hobart PM, Paul M and Dzau VJ (1988). Different secretory pathways of renin from mouse cells transfected with the human renin gene. J. Biol. Chem., 263: 3137-3141.
72. Rasi Hashemi S, Noshad H, Tabrizi A, Mobasseri M, Tayebi Khosroshahi H, Heydarnejad M, Khalaj MR and Aghamohammadzadeh N (2012). Angiotensin receptor blocker and N-acetyl cysteine for reduction of proteinuria in patients with type 2 diabetes mellitus. Iran J. Kidney Dis., 6: 39-43.
73. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T and Remuzzi G (1993). Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J. Am. Soc. Nephrol., 4: 40-49.
74. Renke M, Tylicki L, Rutkowski P, Neuwelt A, Larczynski W, Zietkiewicz M, Aleksandrowicz E, Lysiak-Szydlowska W and Rutkowski B (2010). Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochim. Pol., 57: 547-552.
75. Rigat B, Hubert C, Corvol P and Soubrier F (1992). PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res., 20: 1433.
76. Robles NR, Velasco J, Espinosa J, Mena C and Angulo E (2011). Persistent microalbuminuria after treatment with renin-angiotensin axis blockers: causes and results of treatment intensification. J. Renin Angiotensin Aldosterone Syst., 12: 333-339.
77. Rossing K, Jacobsen P, Pietraszek L and Parving HH (2003). Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care, 26: 2268-2274.
78. Ruggenenti P, Bettinaglio P, Pinares F and Remuzzi G (2008). Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin. J. Am. Soc. Nephrol., 3: 1511-1525.
79. Ruggenenti P, Cravedi P and Remuzzi G (2010). The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat. Rev. Nephrol., 6: 319-330.
80. Russo P, Lauria F, Loguercio M, Barba G, Arnout J, Cappuccio FP, de Lorgeril M, Donati MB, Iacoviello L, Krogh V, van Dongen M and Siani A (2007). - 344C/T Variant in the promoter of the aldosterone synthase gene (CYP11B2) is associated with metabolic syndrome in men. Am. J. Hypertens., 20: 218-222.
81. Rutter MK, Prais HR, Charlton-Menys V, Gittins M, Roberts C, Davies RR, Moorhouse A, Jinadev P, France M, Wiles PG, Gibson JM, Dean J, Kalra PA, Cruickshank JK and Durrington PN (2011). Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1). Diabet. Med., 28: 100-108.
82. Saggar-Malik AK, Afzal AR, Swissman JS, Bland M, Sagnella GA, Eastwood JB, MacGregor GA and Jeffery S (2000). Lack of association of ACE/angiotensinogen genotype with renal function in autosomal dominant polycystic kidney disease. Genet Test, 4: 299-303.
83. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P and Parving HH (2006). Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int., 70: 536-542.
84. Shishido T, Konta T, Nishiyama S, Miyashita T, Miyamoto T, Takasaki S, Nitobe J, Watanabe T, Takeishi Y and Kubota I (2011). Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets). Clin. Exp. Hypertens., 33: 117-123.
85. Siragy HM, Inagami T, Ichiki T and Carey RM (1999). Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc. Natl. Acad. Sci. U. S. A., 96: 6506-6510.
86. Slagman MC, Waanders F, Vogt L, Damman K, Hemmelder M, Navis G and Laverman GD (2012). Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and antiproteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients. Nephrol. Dial. Transplant., 27: 983-990.
87. Song JH, Cha SH, Lee HJ, Lee SW, Park GH and Kim MJ (2006). Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Nephrol. Dial. Transplant., 21: 683-689.
88. Srivastava S, Bhagi S, Kumari B, Chandra K, Sarkar S and Ashraf MZ (2012). Association of polymorphisms in angiotensin and aldosterone synthase genes of the renin-angiotensin-aldosterone system with high-altitude pulmonary edema. J. Renin Angiotensin Aldosterone Syst., 13: 155-160.
89. Stas SN, El-Atat FA and Sowers JR (2004). Pathogenesis of hypertension in diabetes. Rev. Endocr. Metab. Disord., 5: 221-225.
90. Stohr R and Marx N (2012). Renin-Angiotensin-aldosterone system antagonists and the prevention of type 2 diabetes mellitus. Curr. Pharm. Des., 18: 958-962.
91. Suzuki K, Nakagawa O and Aizawa Y (2008). Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clin. Exp. Hypertens., 30: 309-314.
92. Tan F, Mukherjee JJ, Lee KO, Lim P and Liew CF (2010). Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. Singapore Med. J., 51: 151-156.
93. Tang SC, Lin M, Tam S, Au WS, Ma MK, Yap DY, Ho YW and Lai KN (2012). Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrol. Dial. Transplant., 27: 613-618.
94. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Ricard S, Poirier O and Parving HH (1996).Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. Diabetes, 45: 367-369.
95. Taymans SE, Pack S, Pak E, Torpy DJ, Zhuang Z and Stratakis CA (1998). Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J. Clin. Endocrinol. Metab., 83: 1033-1036.
96. Thomas GN, Tomlinson B, Chan JC, Sanderson JE, Cockram CS and Critchley JA (2001). Renin-angiotensin system gene polymorphisms, blood pressure, dyslipidemia, and diabetes in Hong Kong Chinese: a significant association of tne ACE insertion/deletion polymorphism with type 2 diabetes. Diabetes Care, 24: 356-361.
97. Toh S, Reichman ME, Houstoun M, Ross Southworth M, Ding X, Hernandez AF, Levenson M, Li L, McCloskey C, Shoaibi A, Wu E, Zornberg G and Hennessy S (2012). Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch. Intern. Med., 172: 1582-1589.
98. Tylicki L, Lizakowski S, Rutkowski P, Renke M, Sulikowska B, Heleniak Z, Donderski R, Bednarski R, Przybylska M, Manitius J and Rutkowski B (2012). The enhanced renin-angiotensin-aldosteron system pharmacological blockade - which is the best? Kidney Blood Press. Res., 36: 335-343.
99. Uzu T, Sakaguchi M, Yokomaku Y, Kume S, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Koya D, Haneda M and Kashiwagi A (2009). Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clin. Exp. Nephrol., 13: 300-306.
100. Uzu T, Sawaguchi M, Maegawa H and Kashiwagi A (2008). Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART). Hypertens. Res., 31: 1171-1176.
101. Van Buren PN, Adams-Huet B and Toto RD (2010). Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. J. Investig. Med., 58: 950-956.
102. Vardeny O, Pouleur AC, Takeuchi M, Appelbaum E, Verma A, Prescott M, Smith B, Dahlof B and Solomon SD (2012). Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression. J. Renin Angiotensin Aldosterone Syst., 13: 265-272.
103. Vogt L, Waanders F, Boomsma F, de Zeeuw D and Navis G (2008). Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J. Am. Soc. Nephrol., 19: 999-1007.
104. Waanders F, Vaidya VS, van Goor H, Leuvenink H, Damman K, Hamming I, Bonventre JV, Vogt L and Navis G (2009). Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am. J. Kidney Dis., 53: 16-25.
105. Wang J, Zhu X, Yang L, Liu Y, Zhou W and Li H (1999). Relationship between angiotensinogen gene M235T variant with diabetic nephropathy in Chinese NIDDM. Chin. Med. J. (Engl). 112: 797-800.
106. Weir MR, Hollenberg NK, Remuzzi G, Zappe DH, Meng X and Parving HH (2011). Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. J. Hypertens., 29: 2031-2037.
107. Weir MR, Hollenberg NK, Zappe DH, Meng X, Parving HH, Viberti G and Remuzzi G (2010). Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J. Hypertens., 28: 186-193.
108. White PC and Slutsker L (1995). Haplotype analysis of CYP11B2. Endocr. Res., 21: 437-442.
109. Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, Eyileten T, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B and Stenvinkel P (2009). Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. Clin. J. Am. Soc. Nephrol., 4: 535-541.
110. Yoneda T, Takeda Y, Usukura M, Oda N, Takata H, Yamamoto Y, Karashima S and Yamagishi M (2007). Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am. J. Hypertens., 20: 1329-1333.
111. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R and Dagenais G (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med., 342: 145-153.
112. Zaman MA, Oparil S and Calhoun DA (2002). Drugs targeting the renin-angiotensin-aldosterone system. Nat. Rev. Drug Discov., 1: 621-636.
113. Ziyadeh FN (1993). Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int., 43: 114-120.